Compile Data Set for Download or QSAR
Report error Found 8 Enz. Inhib. hit(s) with all data for entry = 11505
TargetDNA (cytosine-5)-methyltransferase 1(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM621246(US11771711, Example 2)
Affinity DataIC50: 54nMAssay Description:This assay used Scintillation Proximity technology in a signal increase format to evaluate the potency of compounds. Full-length human DNMT1, hemi-me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2023
Entry Details
US Patent

TargetDNA (cytosine-5)-methyltransferase 1 [601-1600](Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM491448(US10975056, Example 422 | US11771711, Reference co...)
Affinity DataIC50: 79nMAssay Description:This assay used Scintillation Proximity technology in a signal increase format to evaluate the potency of compounds. Human truncated DNMT1(601-1600),...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2023
Entry Details
US Patent

TargetDNA (cytosine-5)-methyltransferase 1(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM491120(US10975056, Example 64 | US10975056, Example 308 |...)
Affinity DataIC50: 89nMAssay Description:This assay used Scintillation Proximity technology in a signal increase format to evaluate the potency of compounds. Full-length human DNMT1, hemi-me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2023
Entry Details
US Patent

TargetDNA (cytosine-5)-methyltransferase 1(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM621248(US11771711, Example 4 | 4-(2-amino-1-((3,5-dicyano...)
Affinity DataIC50: 107nMAssay Description:This assay used Scintillation Proximity technology in a signal increase format to evaluate the potency of compounds. Full-length human DNMT1, hemi-me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2023
Entry Details
US Patent

TargetDNA (cytosine-5)-methyltransferase 1(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM491224(US10975056, Example 168 | US11771711, Reference co...)
Affinity DataIC50: 156nMAssay Description:This assay used Scintillation Proximity technology in a signal increase format to evaluate the potency of compounds. Full-length human DNMT1, hemi-me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2023
Entry Details
US Patent

TargetDNA (cytosine-5)-methyltransferase 1 [601-1600](Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM491184(US10975056, Example 128 | 2-(4-Chlorophenyl)-2-((3...)
Affinity DataIC50: 631nMAssay Description:This assay used Scintillation Proximity technology in a signal increase format to evaluate the potency of compounds. Human truncated DNMT1(601-1600),...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2023
Entry Details
US Patent

TargetDNA (cytosine-5)-methyltransferase 1(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM621247(US11771711, Example 3)
Affinity DataIC50: 5.21E+3nMAssay Description:This assay used Scintillation Proximity technology in a signal increase format to evaluate the potency of compounds. Full-length human DNMT1, hemi-me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2023
Entry Details
US Patent

TargetDNA (cytosine-5)-methyltransferase 1(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandPNGBDBM621245(US11771711, Example 1)
Affinity DataIC50: 1.61E+4nMAssay Description:This assay used Scintillation Proximity technology in a signal increase format to evaluate the potency of compounds. Full-length human DNMT1, hemi-me...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2023
Entry Details
US Patent